C-fos antisense gene therapy
Latest Information Update: 12 Dec 2001
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 12 Dec 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 21 Feb 1997 Preclinical development for Cancer in USA (Unknown route)
- 20 Feb 1997 New profile